Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) Director Frank Morich bought 15,000 shares of the stock in a transaction dated Thursday, November 12th. The stock was purchased at an average cost of $1.00 per share, with a total value of $15,000.00. Following the completion of the purchase, the director directly owned 15,000 shares in the company, valued at approximately $15,000. This trade represents a ? increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.
Perspective Therapeutics Stock Performance
CATX stock opened at $0.92 on Tuesday. Perspective Therapeutics, Inc. has a twelve month low of $0.78 and a twelve month high of $6.16. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.61 and a current ratio of 5.18. The business has a fifty day moving average of $2.06 and a 200-day moving average of $3.43.
Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. Perspective Therapeutics had a negative net margin of 55,866.82% and a negative return on equity of 42.25%. As a group, equities research analysts predict that Perspective Therapeutics, Inc. will post -1.01 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of analysts recently weighed in on CATX shares. BMO Capital Markets reiterated an “outperform” rating on shares of Perspective Therapeutics in a research report on Friday, October 30th. Royal Bank Of Canada lowered shares of Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their target price for the stock from $14.00 to $4.00 in a research note on Monday, October 26th. Piper Sandler lowered their target price on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Bank of America dropped their target price on Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Friday, August 14th. Finally, William Blair assumed coverage on shares of Perspective Therapeutics in a research note on Friday, September 18th. They issued an “outperform” rating on the stock. Nine research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $10.10.
Read Our Latest Stock Analysis on CATX
Institutional Trading of Perspective Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the stock. Commodore Capital LP bought a new position in Perspective Therapeutics in the 1st quarter valued at about $26,424,000. Affinity Asset Advisors LLC raised its holdings in Perspective Therapeutics by 954.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock valued at $13,196,000 after acquiring an additional 2,864,582 shares in the last quarter. Avidity Partners Management LP lifted its position in Perspective Therapeutics by 88.4% during the first quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock worth $25,228,000 after purchasing an additional 2,839,266 shares during the period. Spruce Street Capital LP bought a new stake in shares of Perspective Therapeutics during the 1st quarter worth approximately $10,955,000. Finally, Marshall Wace LLP acquired a new stake in shares of Perspective Therapeutics in the 3rd quarter valued at $4,075,000. Institutional investors own 54.66% of the company’s stock.
Perspective Therapeutics Company Profile
Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.
Read More
- Five stocks we like better than Perspective Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
